SCHEMBL2477299

SCHEMBL2477299

CCCC1CCCN1C1CCN(c2ccc(N3CCC4(CCOCC4)C3=O)c(C(F)(F)F)c2)C1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 13/20 0.42
EBP Q15125 1/20 0.38
KCNH2 Q12809 1/20 0.36
LIPE Q05469 2/20 0.35
DPP4 P27487 2/20 0.34
NOTUM Q6P988 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480681 0.90 HRH3 (0.43) HRH3EBPKCNH2
SCHEMBL2522643 0.89 HRH3 (0.46) HRH3EBPKCNH2LIPENOTUM
SCHEMBL2474463 0.88 HRH3 (0.55) HRH3KCNH2
SCHEMBL2479476 0.84 HRH3 (0.47) HRH3EBPKCNH2LIPE
SCHEMBL2525774 0.83 HRH3 (0.45) HRH3EBPKCNH2
SCHEMBL2478869 0.83 HRH3 (0.59) HRH3EBPKCNH2
SCHEMBL2478863 0.83 HRH3 (0.59) HRH3EBPKCNH2
SCHEMBL2519405 0.81 HRH3 (0.58) HRH3EBPLIPE
SCHEMBL2532654 0.81 EBP (0.53) HRH3EBPKCNH2
SCHEMBL2523060 0.81 HRH3 (0.46) HRH3EBPKCNH2LIPENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373659-B1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-07-30 EP claimed
US-8217052-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2012-07-10 US claimed
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-13 US claimed
EP-2373659-B1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-07-30 EP disclosed
EP-2373659-B1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-07-30 EP disclosed
US-8383814-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2013-02-26 US disclosed
US-8383814-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2013-02-26 US disclosed
US-20120238757-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-20 US disclosed
US-20120238757-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-20 US disclosed
US-8217052-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2012-07-10 US disclosed
US-8217052-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2012-07-10 US disclosed
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-13 US disclosed
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-13 US disclosed
EP-2373659-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-12 EP disclosed
WO-2010065798-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-06-10 WO disclosed
WO-2010065798-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF HRH3, HRH4, HRH1 HRH3 1/4885EBP 2737/4885KCNH2 1947/4885
US-20120238757-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF HRH3, HRH4, HRH1 HRH3 1/4885EBP 2737/4885KCNH2 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.